AT
Alex Thompson Stifel Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
Ascendis Pharma
ASND
$12.5B
| $205.91 | $254 |
23%
upside
| Buy | 29 days ago |
|
2
Cullinan Oncology
CGEM
$413M
| $6.99 | $22 |
215%
upside
| Buy | 2 months ago |
|
3
Kymera Therapeutics
KYMR
$3.11B
| $43.51 | $55 |
26%
upside
| Buy | 3 months ago |
|
4
Travere Therapeutics
TVTX
$1.93B
| $21.64 | $23 |
6%
upside
| Hold | 4 months ago |
|
5
Crinetics Pharmaceuticals
CRNX
$3.35B
| $35.61 | $60 |
68%
upside
| Buy | 5 months ago |
|
|
ORKA
6
Oruka Therapeutics, Inc. Common Stock
ORKA
$612M
| $16.35 | $49 |
200%
upside
| Buy | 11 months ago |
|
7
argenx
ARGX
$45.9B
| $750.78 | $500 |
33%
downside
| Buy | 1 year ago |
|
8
Spyre Therapeutics
SYRE
$1.03B
| $17 | $54 |
218%
upside
| Buy | 1 year ago |
|
9
Dianthus Therapeutics
DNTH
$853M
| $26.50 | $44 |
66%
upside
| Buy | 1 year ago |
|
10
MoonLake Immunotherapeutics
MLTX
$3.77B
| $59.44 | $69 |
16%
upside
| Buy | 1 year ago |
|
11
Viridian Therapeutics
VRDN
$1.53B
| $18.72 | $40 |
114%
upside
| Buy | 2 years ago |
|
12
Immunovant
IMVT
$2.99B
| $17.14 | $34 |
98%
upside
| Buy | 2 years ago |
|